...
首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis
【24h】

Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis

机译:甲氨蝶呤单独或与羟氯喹联用对类风湿关节炎患者的疗效和安全性的比较评价

获取原文
           

摘要

Background: Rheumatoid arthritis (RA) a chronic autoimmune inflammatory disease and Methotrexate being widely used as monotherapy and in combination for the treatment of RA. Combination therapy provides additional or even more potentiating effects, therefore have been widely used. This study is aimed at comparing the efficacy and safety of Methotrexate either alone or in combination. Methods: This study was conducted for one year from 1 st January to 31 st December 2015. 52 patients diagnosed with RA were included in this study and were divided in two groups, Group-1 (n=29) patients received methotrexate (MTX) 7.5-15mg/week and Group-2 (n=23) patients received methotrexate 7.5mg once a week + Hydroxychloroquine (HCQ) 200mg twice daily. The patients were followed up for a period of 16 weeks. Statistical analysis was done by using graph pad insta and p value of 0.05) in both the groups. Total of Adverse drug reactions reported were 42 (50.60%) in group-1 and 41 (49.40%) in group-2. Conclusions: The combination therapy was found to be more efficacious than MTX monotherapy in improving symptoms and quality of life. The adverse drug reactions were mild, more in combination therapy and none of the patients required withdrawal of treatment.
机译:背景:类风湿关节炎(RA)是一种慢性自身免疫性炎性疾病,甲氨蝶呤被广泛用作单一疗法或联合用于治疗RA。联合疗法可提供更多甚至更大的增强作用,因此已被广泛使用。这项研究旨在比较单独或联合使用甲氨蝶呤的疗效和安全性。方法:本研究从2015年1月1日至12月31日进行,为期一年。本研究纳入52例确诊为RA的患者,分为两组,第1组(n = 29)接受甲氨蝶呤(MTX)治疗每周7.5-15mg和第2组(n = 23)的患者每周接受一次7.5mg甲氨蝶呤+每天两次接受200mg羟氯喹(HCQ)。对患者进行了为期16周的随访。两组均使用graphpad insta和p值(0.05)进行统计分析。第一组的不良药物反应报道总数为42(50.60%),第二组为41(49.40%)。结论:发现联合疗法在改善症状和生活质量方面比MTX单一疗法更有效。药物不良反应较轻,联合治疗更多,无一例患者需要停药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号